Our Translational Research Platform for Metabolic Disease
SBH SCIENCESMetabolic Disease Research Center
We partner with industry and academic institutions to support drug development across a broad range of metabolic disorders and MASH by providing comprehensive disease modeling state-of-the-art functional assays, and biomarker discovery and development services.
Our In-Vitro Models, Biomarker Platforms, and Functional Assays
We have developed a platform of functional assays in a growing range of in vitro models to support drug development programs for key indications in metabolic disease drug development including:
- Insulin Resistance & Type 2 Diabetes
- Obesity & Adipose Dysfunction
- Metabolic Syndrome
- MASH/MASLD
- Advanced MASH & Fibrosis

3T3-L1 Preadipocytes/
Adipocytes
- Adipocyte Differentiation (Adipogenesis) Assay
- Insulin-Stimulated Glucose Uptake Assay
- Lipolysis and Lipid Mobilization Assay
- Adipokine Secretion Profiling
- Mitochondrial Function & Energy Metabolism Assay
- Inflammation-Induced Insulin Resistance Assay
Hepatocytes
(primary & cell lines)
- Hepatotoxicity & Cellular Stress Response
- Lipid Metabolism & Steatosis
- Glucose Metabolism & Insulin Signaling
- Bile Acid Transport & Cholestasis Risk
- Inflammation, ER Stress & Fibrotic Signaling
Pancreatic β-cells
- Glucose-Stimulated Insulin Secretion
- Insulin Content & Processing
- Calcium Signaling
- Mitochondrial Function & Bioenergetics
- β-Cell Survival & Stress Response
Biofluid Protein Biomarkers
| Biomarker | Indication |
|---|---|
| IGF-1 | Insulin Resistance & Glycemic Control |
| Adiponectin | Adipose Dysfunction |
| Leptin | Adipose Dysfunction |
| hsCRP | Systemic Inflammation |
| IL-6 | Systemic Inflammation |
| TNF-α | Systemic Inflammation |
| CK-18 (M30/M65) | Hepatocyte Injury/ Apoptosis |
| PIIINP | Fibrosis & ECM Remodeling |
| sCD163 | Hepatic Inflammation |
| Galectin-3 |
Hepatic Inflammation/Fibrosis |
| FGF21 | Metabolic Stress Hormone |
| MMP-2/MMP-9 | Fibrosis and Remodeling |
